Biodesix to Participate in Two Investor Conferences in June

Rhea-AI Summary

Biodesix, a diagnostic solutions company specializing in lung disease, has announced its participation in two investor conferences in June 2024. CEO Scott Hutton will present at the William Blair 44th Annual Growth Stock Conference on June 4 in Chicago, IL, at 10:40 AM CT. He will also present at the Jefferies Global Healthcare Conference on June 6 in New York, NY, at 8:30 AM ET. Both presentations will be webcast live and available for replay in the Investors section of Biodesix's website.

Positive

• Biodesix's active participation in two major investor conferences indicates strong investor relations efforts.
• The CEO's direct engagement may provide valuable insights and boost investor confidence.
• Webcast availability ensures accessible information for a broader audience, potentially increasing investor interest.

Negative

• No new product or financial data announcements were mentioned, which may disappoint investors seeking substantial updates.
• The emphasis on presentations without concrete business updates might be perceived as lacking significant progress.

LOUISVILLE, Colo.--(BUSINESS WIRE)-- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, today announced Scott Hutton, Chief Executive Officer, will participate in two upcoming investor conferences:

William Blair 44^th Annual Growth Stock Conference
Presentation and 1x1 Meetings
Presentation Date and Time: Tuesday, June 4, 2024 at 10:40 AM CT
Location: Chicago, IL

Jefferies Global Healthcare Conference
Presentation and 1x1 Meetings
Presentation Date and Time: Thursday, June 6, 2024 at 8:30 AM ET
Location: New York, NY

The presentations will be webcast live and available for replay under “News & Events” in the Investors section of the Company's website at www.biodesix.com.

About Biodesix

Biodesix is a leading diagnostic solutions and services company with a focus in lung disease. Biodesix offers five Medicare-covered tests for patients with lung diseases. The blood-based Nodify Lung® Nodule Risk Assessment testing strategy, consisting of the Nodify XL2® and the Nodify CDT® tests, evaluates the risk of malignancy in incidental pulmonary nodules, enabling physicians to better triage patients to the most appropriate course of action. The blood-based IQLung™ strategy for lung cancer patients integrates the GeneStrat® targeted ddPCR™ test, the GeneStrat NGS® test and the VeriStrat® test to support treatment decisions across all stages of lung cancer with results in an average of two to three business days, expediting the time to treatment. Biodesix collaborates with many of the world’s leading biotechnology and pharmaceutical companies to solve complex diagnostic challenges in lung disease. For more information about Biodesix, visit biodesix.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240528693998/en/

Media:

Natalie St. Denis

natalie.stdenis@biodesix.com

(720) 925-9285



Investors:

Chris Brinzey

chris.brinzey@westwicke.com

(339) 970-2843

Source: Biodesix, Inc.

FAQ

When is Biodesix presenting at the William Blair 44th Annual Growth Stock Conference?

Biodesix will present at the William Blair 44th Annual Growth Stock Conference on June 4, 2024, at 10:40 AM CT.

What time is Biodesix's presentation at the Jefferies Global Healthcare Conference?

Biodesix will present at the Jefferies Global Healthcare Conference on June 6, 2024, at 8:30 AM ET.

Where can I watch Biodesix's investor conference presentations?

The presentations will be webcast live and available for replay under the 'News & Events' section in the Investors area of the Biodesix website.

Who will represent Biodesix at the upcoming investor conferences?

Scott Hutton, the CEO of Biodesix, will represent the company at the investor conferences.

What is the stock symbol for Biodesix?

The stock symbol for Biodesix is BDSX.